AstraZeneca Pharma India gets approval for Imfinzi in liver cancer treatment

AstraZeneca Pharma India got CDSCO approval to market Durvalumab for unresectable hepatocellular carcinoma, expanding its oncology portfolio. Shares closed 0.33% higher at ₹8,403.

Leave a Reply

Your email address will not be published. Required fields are marked *